Anjalee Khemlani

1 week ago | aol.com | Anjalee Khemlani

Moderna's (MRNA) stock was up slightly in pre-market trading Thursday despite an announcement that the National Institutes of Health (NIH), led by Robert F. Kennedy Jr., is ending a $750 million-plus contract to develop its bird flu vaccine late Wednesday. "Moderna received notice that HHS will terminate the award for the late-stage development and right to purchase pre-pandemic influenza vaccines," Moderna said in a statement late Wednesday.

2 weeks ago | ca.finance.yahoo.com | Anjalee Khemlani

Hinge Health (HNGE), a digital health platform for physical therapy, debuted on the New York Stock Exchange at $32 per share Thursday and rising shortly after trading to $39. The company announced it would go public in March, marking the second time it would attempt to do so. It was valued at nearly $6.2 billion in 2022, when it first announced plans. Hinge aimed for a $3 billion valuation for Thursday, offering 13.7 million shares on the market.

2 weeks ago | ca.finance.yahoo.com | Anjalee Khemlani

Novo Nordisk (NVO) is offering a one-month reduction in the price of its blockbuster weight-loss GLP-1 drug, to help encourage new patients to use the branded drug, as compounded copycats are forced off the market. "This one-time offer is intended to help patients who have previously been prescribed unapproved or illicit 'semaglutide' drugs and are seeking access to authentic, FDA-approved Wegovy," the company said in a statement Thursday.

2 weeks ago | ca.finance.yahoo.com | Anjalee Khemlani

In November 2024, UnitedHealth Group's (UNH) stock appeared to be on an unstoppable upward trajectory, reaching an all-time high of $625 per share. It had seemingly survived the largest cyberattack in healthcare history and overcame two years of elevated Medicare Advantage costs — a headwind that plagued the entire insurance industry last year.

2 weeks ago | ca.finance.yahoo.com | Anjalee Khemlani

DNA testing company 23andMe (MEHCQ) is being purchased out of bankruptcy by large-cap drugmaker Regeneron (REGN), for $256 million. The deal includes "substantially all assets," but excludes the telehealth platform, pharmacy fulfillment business, and lab and test ordering services under Lemonaid Health, according to the agreement filed in the US Bankruptcy Court in the Eastern District of Missouri. The deal is scheduled to close July 1.